|
|
|
|
|
|
|
|
Controversies Continue in NCCN Ovarian Cancer Guidelines
Medscape Medical News from the:
National Comprehensive Cancer Network (NCCN) 17th Annual Conference
This coverage is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.
From Medscape Medical News > Conference News
Controversies Continue in NCCN Ovarian Cancer Guidelines
Neoadjuvant Chemotherapy and CA-125 Reviewed
March 20, 2012 (Hollywood, Florida) — The ovarian cancer
guidelines from the National Comprehensive Cancer Network (NCCN) address
a number of ongoing controversies, according to a presenter here at the
NCCN 17th Annual Conference.
One such controversy is about the usefulness of the biomarker CA-125 to monitor patients who have been treated with surgery and/or chemotherapy. Dr. Morgan called CA-125 the "most controversial" aspect of patient follow-up.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.